|Mr. Donald J. McCaffrey||Co-Founder, Chairman, Pres, CEO & Sec.||505.2k||N/A||N/A|
|Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV||Chief Financial Officer||281.8k||N/A||N/A|
|Mr. Kenneth Eugene Lebioda BA||Sr. VP of Bus. & Corp. Devel.||264.6k||N/A||N/A|
|Dr. Michael Sweeney||Sr. VP of Clinical Devel.||525.29k||N/A||1961|
|Dr. Ewelina Kulikowski||Sr. VP of Scientific Devel.||250k||N/A||N/A|
|Dr. Norman C.W. Wong B.Sc., FRCPC, M.Sc., B.Sc (Hon), M.Sc, M.D., FRCP(||Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board||N/A||N/A||N/A|
|Sarah Zapotichny||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Jan O. Johansson||Sr. VP of Medical Affairs||N/A||N/A||N/A|
Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular, end-stage renal, chronic kidney, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.